|
May 15
|
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
|
|
May 15
|
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
|
|
May 15
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
May 14
|
Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
|
|
May 13
|
Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
|
|
May 12
|
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
|
|
May 12
|
Teva's Bold $700M Gamble: Will It Be Enough to Rescue Its Plummeting Stock?
|
|
May 9
|
Teva Pharmaceutical Industries Limited (TEVA): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential
|
|
Apr 28
|
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
|
|
Apr 21
|
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now
|
|
Mar 14
|
Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma
|
|
Mar 11
|
Teva debuts global campaign encouraging people to get outside
|
|
Feb 24
|
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
|
|
Feb 24
|
Teva and Alvotech launch ustekinumab biosimilar injection in US
|
|
Feb 24
|
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
|
|
Feb 22
|
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
|
|
Feb 21
|
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
|
|
Feb 20
|
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
|
|
Feb 19
|
Is Teva Pharmaceutical (TEVA) Trading at a Discount?
|
|
Feb 18
|
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
|